Biontech SE

Ugur Sahin, Chief Executive Officer and 10% owner of BioNTech SE, sold 66,000 shares of common stock on September 29, 2026.

Ugur Sahin, Chief Executive Officer and 10% owner of BioNTech SE, sold 61,000 shares of common stock on September 25, 2026.

Ugur Sahin, Chief Executive Officer and 10% owner of BioNTech SE, sold 69,000 shares of common stock on September 23, 2026.

Ugur Sahin, Chief Executive Officer and 10% owner of BioNTech SE, sold 79,000 shares of common stock on September 21, 2026.

Ugur Sahin, Chief Executive Officer and 10% owner of BioNTech SE, sold 64,000 shares of common stock on September 17, 2026.

Ugur Sahin, Chief Executive Officer and 10% owner of BioNTech SE, sold 86,000 shares of common stock on September 11, 2026.

ATHOS KG, AT Impf GmbH, and Thomas Maier maintain a 40.2% beneficial ownership stake in BioNTech SE.

Medine GmbH and Prof. Ugur Sahin, M.D. have jointly filed an amendment to their Schedule 13G, reaffirming their substantial beneficial ownership in BioNTech SE, with Prof. Sahin holding 17.6% and Medine GmbH holding 16.7% of the ordinary shares.